Skip to content

Study on the effectiveness of Ketamine in persons suffering from bipolar depression

A randomised clinical study on the effectiveness of Ketamine vs Placebo in the treatment of bipolar depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/10/037093
Enrollment
80
Registered
2021-10-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F313- Bipolar disorder, current episodedepressed, mild or moderate severity Health Condition 2: F314- Bipolar disorder, current episodedepressed, severe, without psychotic features

Interventions

Intervention1: Ketamine infusion: Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Sub-anesthetic (low) doses will be given to patients via infusion

Sponsors

Ahana hospitals LLP
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Written informed consent. Patients diagnosed with bipolar affective disorder current episode depression as per ICD 10 guidelines Patients started on antidepressants specifically SNRIs

Exclusion criteria

Exclusion criteria: Co-morbid psychiatric diagnoses such as psychosis, substance dependence Mental retardation, neurological disorders, and severe medical illness Pregnancy or breastfeeding Allergy to ketamine

Design outcomes

Primary

MeasureTime frame
Patient reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) â?? approximately 7th day] Response is defined as at least a 50% improvement in Baseline HAM-D score at End of Treatment Visit. The End of Treatment Visit will occur 7th day after the Baseline Visit. Timepoint: Patient reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) â?? approximately 7th day] Response is defined as at least a 50% improvement in Baseline HAM-D score at End of Treatment Visit. The End of Treatment Visit will occur 7th day after the Baseline Visit.

Secondary

MeasureTime frame
clinician reported response to treatment [ Time Frame: Acute Study Phase (Baseline Visit to End of Treatment Visit) - approximately 7th day ] Number of patients with an improvement in their Baseline CGI score at the End of Treatment Visit. The End of Treatment Visit will occur in 7th day after the Baseline Visit. Timepoint: baseline and 7th day

Countries

India

Contacts

Public ContactVikhram Ramasubramanian

Ahana hospitals, LLP

vikhram@ahanahospitals.in09443772233

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026